Vedolizumab Trough level
Category | Immunology |
---|---|
Test background |
Vedolizumab (Entyvio©) is a humanised IgG1 antibody which inhibits the action of the mucosal trafficking α4β7 integrin and prevents migration of inflammatory T cells to the gut. Vedolizumab levels are measured in serum taken from patients just before an infusion (trough) using an indirect ELISA coated with α4β7 integrin |
Clinical Indications |
For the monitoring of drug trough levels in IBD patients treated with Vedolizumab |
Reference range | Results are reported between 0.8 µg/ml and 144 µg/ml. In the induction phase of the Entyvio© clinical trials week 6 trough levels were higher in responders than non-responders and higher trough levels were associated with increased mucosal healing in UC patients. |
Sample & container required | Serum (rust top) vacutainer |
Sample volume | 0.5ml |
Sample collection | Samples should be taken just before the next infusion of drug (trough) |
Transport storage | Transportation at room temperature/ first class post is adequate. Storage at 4 degrees or -20 for long term. |
Turnaround time | 4 weeks |